Ibrutinib Increases Hypertension and Cardiovascular Risk

For patients with B-cell malignancies, the hypertension caused or worsened by treatment with ibrutinib results in a two-fold increased risk of major adverse cardiovascular events, report researchers at The Ohio State University. Ibrutinib can be highly effective against B-cell malignancies such as mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenstrom macroglobulinemia. However, it also is associated with cardiotoxicity. Severe hypertension has been reported, but "the long-term inci...
Continue reading

Epidermal Growth Factor Ointment for Skin Toxicities: An Interview With Sung Yong Oh, MD, PhD

By inhibiting epidermal growth factor receptor (EGFR) signaling pathways, EGFR inhibitors have shown efficacy in the treatment of a variety of cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer. However, most patients who receive EGFR inhibitors develop adverse skin events, such as acneiform rash, xerosis, paronychial inflammation, pruritis, photosensitivity, and hair and eyelash alteration. If not properly managed, these toxicities can lead to physic...
Continue reading

Hyperbaric Oxygen Therapy Relieves Late Radiation Cystitis Symptoms

A debilitating side effect of radiotherapy, late radiation cystitis occurs in patients six months after completing treatment and involves the urinary bladder becoming inflamed and destroyed. Hyperbaric oxygen therapy, which involves breathing pure oxygen in a pressurized room or tube, is a potential treatment for late radiation cystitis; however, much of the evidence of this treatment being effective is based on non-randomized and retrospective studies. Researchers set out to determine if hyperb...
Continue reading

Pre-Immunotherapy Antibiotics Drastically Reduce Survival

An observational study reports that broad-spectrum antibiotic treatment administered within 30 days prior to the commencement of immune checkpoint inhibitor therapy dramatically worsens overall survival and increases the risk of treatment-refractory disease. Published in JAMA Oncology , the prospective cohort study conducted at two tertiary academic referral centers enrolled 196 patients with cancer receiving immune checkpoint therapy for non-small cell lung cancer (119 patients), melanoma (38 p...
Continue reading

Epidermal Growth Factor Ointment Relieves Skin Toxicities

A new study reports that epidermal growth factor (EGF) ointment is effective in managing skin toxicities and improving quality of life in patients treated with epidermal growth factor receptor (EGFR) inhibitors. By inhibiting EGFR signaling pathways, which play a role in the pathogenesis and progression of a variety of cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer, EGFR tyrosine kinase inhibitors and anti-EGFR monoclonal antibodies are effective ...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.